SEC Form 4 · accession 0001197350-26-000007
Mirum Pharmaceuticals, Inc. · MIRM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Eric Bjerkholt
Officer — CHIEF FINANCIAL OFFICER
Period of report
Jun 8, 2026
Accepted (ET)
Jun 9, 2026 · 9:21 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001759425
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Jun 8, 2026 | S | 2,258 | $92.84 | D | 47,530 | D | |
| Common StockF3 | Jun 8, 2026 | S | 1,175 | $93.95 | D | 46,355 | D | |
| Common StockF4 | Jun 8, 2026 | S | 1,567 | $95.12 | D | 44,788 | D | |
| Common Stock | Jun 9, 2026 | M | 2,393 | $26.49 | A | 47,181 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F5 | $26.49 | Jun 9, 2026 | M | 2,393 | D | — | Jan 22, 2034 | Common Stock | 2,393 | 26,653 | D |
Explanation of responses
- F1Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on March 9, 2026.
- F2. The weighted average sale price for the transaction reported was $92.84, and the range of prices were between $92.485 and $93.31. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- F3. The weighted average sale price for the transaction reported was $93.95, and the range of prices were between $93.49 and $94.47. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- F4. The weighted average sale price for the transaction reported was $95.12, and the range of prices were between $94.62 and $95.44. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- F51/4th of the shares vested one year after January 23, 2024 (the "Vesting Commencement Date") and the balance of the shares vest in a series of 36 successive equal monthly installments measured from the first anniversary of the Vesting Commencement Date.